Press Digest: Financial Times - June 9
PRESS DIGEST-Financial Times - June 9 June 9 (Reuters) - The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy.
Headlines
GSK in talks to buy cancer biotech Nuvalent for more than $9 billion
AstraZeneca advances weight-loss pill to take aim at obesity leaders
Berlin pulls plug on Franco-German fighter jet
UK FCA seeks High Court injunction against Neil Woodford over new online service
Overview
UK pharmaceutical group GSK GSK.L is in talks to buy cancer drugmaker Nuvalent NUVL.O for more than $9 billion.
AstraZeneca AZN.L said participants in a Phase 2 trial shed 11.8% of their weight after 36 weeks on elecoglipron, a daily GLP-1 pill.
Germany has informed France that it wants to withdraw from plans to develop a joint fighter jet, dealing a potentially fatal blow to Europe's largest defense programme.
The UK financial regulator has started legal proceedings against Neil Woodford, alleging the fund manager is providing unauthorised investment advice through W4.0, his new service offering customers access to his investment strategies.
(Compiled by Bengaluru newsroom)
Recent news on AstraZeneca
See all newsUK Market Exodus: Companies that moved away from London listing in recent years
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Race to launch weight-loss pill heats up as Novo wins UK approval
Project Nashville: GSK boosts oncology rebuild with $11 billion Nuvalent deal (updated)
Project Nashville: GSK boosts oncology rebuild with $11 billion Nuvalent deal